U.S., Dec. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07277504) titled 'Autologous Bedside CD19 CAR T-cell Therapy for B-ALL' on Nov. 20.
Brief Summary: The purpose of this clinical trial is to learn if autologous bedside CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy works to treat B-cell acute lymphoblastic leukemia (B-ALL) in adults. It will also learn about the safety and efficacy of the autologous bedside CD19 CAR-T cell product.
The main questions it aims to answer are:
1. What adverse events occur and the incidence rate of dose-limiting toxicities (DLTs) within 28 days and CAR-T-related adverse events (AEs) after the autologous CD19 CAR-T cell infusion for B-ALL?
2. Which dose ...